The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Key presentations in CLL treatment at ASH 2020
Toby Eyre, MBChB (Hons), DipMedEd, MRCP (UK), FRCPath (UK), MD, Oxford University Hospitals NHS Foundation Trust, Oxford, shares some of his top updates in the chronic lymphocytic leukemia (CLL) field presented at ASH 2020. These include the UNITY CLL trial (NCT02612311) which investigated a novel combination (U2) of ublituximab, a CD20 antibody, and umbralisib, a PI3K and casein kinase 1-epsilon inhibitor. Promising survival outcomes were associated with use of U2 when compared to obinutuzumab-chlorambucil use. He also discusses promising toxicity and efficacy findings, consistent across subgroups, from a Phase I/II trial (NCT03740529) of LOXO-305: a novel reversible non-covalent BTK inhibitor. Additionally, data was presented at ASH 2020 that represented a new response-adapted approach to CLL management. The CAPTIVATE trial (NCT02910583) treated patients with fixed duration ibrutinib plus venetoclax therapy before they were randomized to receive ongoing treatment or observation based on their measurable residual disease negativity status, a treatment method new to the CLL field. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
